Skip to content
value.today

ALDEA Pharmaceuticals, Inc.

🇺🇸 Westport, Connecticut, USABiotechnologyFounded 2008
Total raised
$21 M
2 rounds on record
Latest round
$9 M
Aug 2014
First round on record
Sep 2011
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ALDEA Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2014$9 MNo. 2$2 to $10 million

ALDEA Pharmaceuticals, Inc.: Raise no. 2, Aug 2014

Investors in this round

5 investors had bought by the notice of Aug 25, 2014: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $24 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: "Offering of convertible promissory notes (""Notes""), Series B Preferred Stock (""Series B""), the underlying shares of Series B issuable upon conversion of Notes and the underlying shares of Common
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard Shames, M.D. · Executive Officer
  • Vernon Jiang, Ph.D. · Executive Officer
  • Wenjin Yang · Executive Officer
  • William Yelle · Executive Officer, Director
  • Evgeny Zaytsev · Director
  • Howard Rosen · Director
  • John Walker · Director
  • Timothy Shannon · Director
  • Wende Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William E. Yelle, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 25, 2014. Read the notice at the SEC.

equitySEC
Sep 2011$11 MNo. 1$10 to $50 million

ALDEA Pharmaceuticals, Inc.: Raise no. 1, Sep 2011

Investors in this round

6 investors had bought by the notice of Nov 18, 2013: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, other: "Offering of convertible promissory notes (""Notes""), the underlying shares of Series A Preferred Stock issuable upon conversion of the Notes and the underlying shares of Common Stock issuable upon c
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$740 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Wenjin Yang · Executive Officer
  • William Yelle · Executive Officer, Director
  • Howard Rosen · Director
  • John Walker · Director
  • Timothy Shannon · Director
  • Wende Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William E. Yelle, Chief Executive Officer. Source: SEC Form D and 3 amendments, newest notice filed Nov 18, 2013. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ALDEA Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2014).

    SEC Form D · Aug 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2014

That is all the official record says: ALDEA Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of ALDEA Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 6 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ALDEA Pharmaceuticals, Inc.
NameRoleNamed in
Richard Shames, M.D.Executive officerAug 2014
Vernon Jiang, Ph.D.Executive officerAug 2014
Wenjin YangExecutive officerAug 2014
William YelleExecutive officerAug 2014
Timothy ShannonExecutive officerMay 2012
Evgeny ZaytsevDirectorAug 2014
Howard RosenDirectorAug 2014
John WalkerDirectorAug 2014
Timothy ShannonDirectorAug 2014
Wende HuttonDirectorAug 2014
William YelleDirectorAug 2014
Daria Mochly-RosenDirectorMay 2012